Skip to content

A3P Biomedical – Stockholm3 included in Swedish screening program

Region Stockholm and Region Gotland (the Region) have initiated an organized program for prostate cancer testing (OPT) that involves men born in 1974 and 1972 residing in the Region. The OPT program includes the Stockholm3 test to identify men with prostate cancer at an early stage.

On February 12, the first invitations to the OPT program were sent out to men in the Region. A total of 27,000 men born in 1974 and 1972 will be invited to the program and offered Stockholm3 testing at elevated PSA values. The purpose of OPT is to make prostate cancer testing more effective and accurate, and to reach more men who do not test themselves on their own initiative. The use of Stockholm3 aims to detect aggressive prostate cancer at an early stage, reduce overdiagnosis, and improve resource use in healthcare.

This is the second screening program in Sweden to include Stockholm3. Since 2022, Region Värmland has used Stockholm3 in its OPT program, which is offered to all men aged 50 to 70 living in that region.

“The introduction of Stockholm3 in the Region’s OPT program will provide men with the opportunity for an earlier and more accurate diagnosis when the cancer is still curable, enable shorter lead times to treatment, and more efficient resource use in healthcare. This is truly a win-win for both citizens and healthcare,” says David Rosén, CEO of A3P Biomedical.